Health. Quality. Life.
hu en

Our Results

Our net sales revenue was HUF 130 billion in the 2013/2014 financial year (lasting from 1 October 2013 to 30 September 2014). 77% of our revenue derived from export in our key export markets: EUR 159 million in Russia and other CIS-countries, EUR 122 million in Central and Eastern Europe. In our domestic market, Hungary Egis Pharmaceuticals PLC has traditionally been one of the market leaders. Our company ranks third on the basis of the number of packages sold in the Hungarian market. accordance with our strategic goals we launched 5 new products in our markets in the 2013/2014 financial year. At the end of the financial year we had 330 domestic registrations and 2,463 abroad.

Three therapeutic areas are in the focus of our R&D activities: the cardiovascular, the central nervous and the respiratory systems, which altogether account for 73% of our sales revenue. Although we continue to place the main emphasis on these areas, we continuously open towards new therapeutic areas.

The most important key to our competitiveness and our future success is innovation, to which we dedicate an outstanding amount every year. In the 2013/2014 financial year we spent 10% of our sales revenue, HUF 13 billion on research and development.

Our performance is the joint achievement of almost 4,000 colleagues working in Hungary and at our affiliates and subsidiaries in various parts of the world.